This site is intended for healthcare professionals
Artery and Heart muscle under the microscope, pink and purple colours
Lipid management in ASCVD Learning Zone

Advances in ASCVD 2023: Roundtable

Last updated: 5th Dec 2023
Published: 5th Dec 2023
Declaration of sponsorship: Novartis
Lipid management in ASCVD – Overview

Lipid-lowering landscape: Advances in ASCVD from 2023

In this live roundtable, Professors Alberico Catapano, Borge Nordestgaard and Meral Kayıkçıoğlu discuss recent advances in atherosclerotic cardiovascular disease (ASCVD) management presented at key conferences in 2023.

  • How lipid-lowering guidelines are evolving: Their strengths and limitations
  • The experts’ pick of the year’s major research findings
  • Beyond low-density lipoprotein: Novel approaches to managing residual ASCVD risk

Professor Catapano discusses:

  • The latest guidelines for ASCVD management and prevention in clinical practice from the ESC, along with the EAS consensus on lipoprotein(a)
  • Personalising ASCVD treatment based on subpopulations, considering factors like fatty liver disease, obesity, depression and lifestyle
  • The utilisation of CVD risk-assessment tools, screening for risk factors including lipoprotein(a), and novel risk factors from key congresses in 2023

Professor Nordestgaard rounds up the latest data on lipid-lowering in people with high ASCVD risk, including:

  • Insights from the SANTORINI and Copenhagen General Population studies
  • Recent trial data on bempedoic acid and PCSK9 inhibitors and the implications for people at high risk of ASCVD

Professor Kayıkçıoğlu highlights novel approaches to reducing ASCVD risk beyond targeting low-density lipoprotein, including:

  • In-development agents targeting lipoprotein(a) and triglycerides
  • In-progress trials of antisense oligonucleotides and small interfering RNA-based treatments
  • Targeting obesity with glucagon-like peptide-1 receptor agonists

Question 1: How do you personalise treatment plans, given the heterogeneity of responses to lipid-lowering therapies?

Question 2: How do you prioritise lifestyle in the management of CVD?

Question 3: What alternative treatments are available to address statin intolerance?

Question 4: From a clinical perspective, how will new treatment options assist HCPs in the management of patients in daily practice?

Question 5: What biomarkers or patient characteristics guide your treatment decisions?

Meet the experts

Professor Alberico Catapano

Professor Alberico Catapano

Alberico Catapano is Director of the Center for the Study, Prevention and Therapy of Atherosclerosis of the University of Milan at the Bassini Hospital, Italy; Director of Cardiovascular Research Unit at MultiMedica IRCCS Sesto San Giovanni (MI); and Co-Chairman of the EAS/European Society of Cardiology (ESC) guidelines for the treatment of dyslipoproteinaemias and lipid consensus papers. Professor Catapano is interested in the study of atherosclerosis, lipids, lipoproteins and genetic dyslipidaemias, and he has made landmark observations regarding heat shock proteins and pentraxins in atherogenesis, on high-density lipoproteins in the modulation of the immune response, and on the identification of possible therapeutic targets by exploiting genetic information.

Disclosures: Over the last 3 years, Professor Alberico Catapano has received honoraria, lecture fees or research grants from Aegerion Pharmaceuticals, Akcea Therapeutics, Amarin Corporation, Amgen, Amryt Pharma, AstraZeneca, Daiichi Sankyo, Esperion Therapeutics, Ionis Pharmaceuticals, Medscape Education, Menarini, Merck, Mylan, Novartis, PeerVoice, Pfizer, Recordati, Regeneron, Sanofi, The Corpus, and Viatris.

Professor Borge Nordestgaard profile pic

Professor Borge Nordestgaard

Professor Nordestgaard is a Clinical Professor at the University of Copenhagen, Denmark. He has written extensively about the pathogenesis, diagnosis and treatment of familial hypercholesterolemia, hyperlipidaemia, lipoprotein(a), atherosclerosis, diabetes and cardiovascular disease. He chairs the Copenhagen General Population Study and is a steering committee member for the Copenhagen City Heart Study and five phase 3 cardiovascular intervention trials.

Disclosures: Professor Nordestgaard has received consultancies/given talks for Abbott, Amarin, Amgen, AstraZeneca, Denka, Esperion Therapeutics, Ionis Pharmaceuticals, Kowa, Lilly, Mankind, Novartis, Novo Nordisk, Regeneron, Sanofi, Silence Therapeutics, Ultragenyx, and USV.

Professor Meral Kayıkçıoğlu profile pic

Professor Meral Kayıkçıoğlu

Professor Meral Kayıkçıoğlu is a cardiologist at Ege University Medical School, Izmir, Türkiye. She has led various clinics, including the Lipid, Pulmonary Hypertension, and Young MI Clinics. Her research focuses on atherosclerosis, prevention, lipids, familial hypercholesterolemia, rare cardiovascular diseases, and cardiovascular disease in women. Professor Kayıkçıoğlu chairs several national registries, including those for familial hypercholesterolemia, acute myocardial infarction, premature myocardial infarction and peripartum cardiomyopathy.

Disclosures: Over the last 3 years, Professor Kayıkçıoğlu has received honoraria or research grants from Abdi İbrahim, Aegerion Pharmaceuticals, Amgen, Amryt Pharma, AstraZeneca, Daiichi Sankyo, Deva, Esperion Therapeutics, Exeltis, Ionis Pharmaceuticals, Janssen, LIB Therapeutics, Medpace, Menarini, Merck, Novartis, Pfizer, Recordati, Regeneron, Sanofi, and Sanovel.

Welcome:
Register
Updates in your area
of interest
Articles your peers
are looking at
Bookmarks
saved
Days to your
next event